Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy ), By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023

Description

Lysosomal storage diseases (LSDs) are diseases caused by defects in single-genes. Enzyme defects cause nearly seventy percent of the LSDs, and the rest are defects in enzyme activator or associated proteins. A gene on a particular chromosome locus transcribes a particular enzyme, improper enzyme-coding results in inactive enzymes. Similarly, defective activators result from mutations in activator genes. These conditions cause disease of the organs in which they accumulate and decide the clinical signs and symptoms. Infants and children suffer more severely compared to adults. The clinical features are unique in many children and adults for the same disease. For example, the child's developing brain is more susceptible to insults and manifests symptoms and signs of dysfunction, while this may be milder or absent in adults. Enzyme testing is usually the initial diagnostic test, but genetic analysis of the gene mutations adds precision. There are many modern therapeutic techniques for these conditions. When applied early before organ damage sets in, these therapies have the potential to prevent or delay damage, improve quality of life, and increase lifespan.

Market Dynamics

Increasing significance of lysosomal storage diseases, arrangement of awareness programs by governments and the launch of new products are attributed to the growth of the global lysosomal storage diseases therapeutics market. For instance, on May 11, 2023, Chiesi USA, Inc., a U.S. based pharmaceutical company announced that its product Elfabrio was approved by U.S. Food and Drug Administration. It uses the enzyme pegunigalsidase alfa for enzyme replacement therapy (ERT) to treat adults with confirmed Fabry disease.

Key features of the study:

This report provides an in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revaenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lysosomal storage diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lysosomal storage diseases therapeutics market.

Detailed Segmentation:

Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Others
Global Lysosomal Storage Diseases Therapeutics Market, By Indication:
- Gaucher's Disease
- Fabry Disease
- Pompe's Syndrome
- Mucopolysaccharidosis
- Others
Global Lysosomal Storage Diseases Therapeutics Market, By End User:
- Hospitals
- Clinics
Global Lysosomal Storage Diseases Therapeutics Market, By Geography:
- North America
  - By Country:
- U.S.
- Canada
- Europe
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- Central Africa
- South Africa
- North Africa
Company Profiles
- Shire plc*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments
- Pfizer, Inc.
- Sanofi SA
- BioMarin Pharmaceutical Inc
- Actelion Ltd.
- Raptor Pharmaceutical Corp.
- Protalix Biotherapeutics Inc.
- Amicus Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI3651

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Indication
- Market Snapshot, By End user
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Lysosomal Storage Diseases Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Substrate Reduction Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
Gaucher's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Fabry Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Pompe's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Mucopolysaccharidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Lysosomal Storage Diseases Therapeutics Market, By End user, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Lysosomal Storage Diseases Therapeutics Market, By Region, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018 -2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication , 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Shire plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
Sanofi SA
BioMarin Pharmaceutical Inc
Actelion Ltd.
Raptor Pharmaceutical Corp
Protalix Biotherapeutics Inc.
Amicus Therapeutics, Inc.

10. Section

Research Methodology
About Us

Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy ), By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030